1-Cyclopropyl-2-fluoro-4-methylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Cyclopropyl-2-fluoro-4-methylbenzene
• 英文别名: 1-cyclopropyl-2-fluoro-4-methylbenzene
• 化学式: C₁₀H₁₁F
• 分子量: 150.19
• InChiKey: RAMPGRZFWPQIFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20170253609A1

  公开（公告）日：2017-09-07

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了以下式(I)的化合物，或其药学上可接受的盐、酯或前药： X-A-Y-L-R  (I) 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰HBV生命周期的功能，并且还可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• [EN] GPR52 MODULATORS AND METHODS OF USE<br/>[FR] MODULATEURS DE GPR52 ET PROCÉDÉS D'UTILISATION
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2021216705A1

  公开（公告）日：2021-10-28

  The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present disclosure are directed to methods useful in the treatment or prophylaxis of a neurological disease or disorder and conditions related thereto.

  本公开涉及式(I)化合物，该化合物调节G蛋白偶联受体52（GPR52）的活性，化合物的药学可接受盐以及其制备的药物组合物。本公开的化合物、化合物的药学盐以及药物组合物，用于治疗或预防神经系统疾病或障碍及相关疾病的方法。
• IDO INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20160200674A1

  公开（公告）日：2016-07-14

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.

  本发明揭示了一些化合物，可调节或抑制吲哚胺2,3-二氧化酶（IDO）的酶活性，包括含有该化合物的制药组合物，以及利用本发明中的化合物治疗增生性疾病（如癌症、病毒感染和/或自身免疫疾病）的方法。
• [EN] INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE LA GLYCOGÈNE SYNTHASE 1 (GYS1) ET LEURS MÉTHODES D'UTILISATION
  申请人：MAZE THERAPEUTICS INC

  公开号：WO2022198196A1

  公开（公告）日：2022-09-22

  Provided herein are compounds of formula (I') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y2, Y3, L1, L2, X1, X2, X3, X4, X5, Q1, R1, R2, Rk, Rm, and Rnare as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (F). Also provided herein are methods of inhibiting GYS1 and methods of treating a GYS1 -mediated disease, disorder, or condition in an individual in need thereof.

  本文提供了公式(I')的化合物或其立体异构体或互变异构体，或任何其药学上可接受的盐，其中Y2，Y3，L1，L2，X1，X2，X3，X4，X5，Q1，R1，R2，Rk，Rm和Rn的定义在本文其他部分中已经说明。本文还提供了制备公式(F)化合物的方法。本文还提供了抑制GYS1的方法以及治疗需要该方法的个体中的GYS1介导的疾病，障碍或状况的方法。
• [EN] CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS INDANYLES CONTENANT DE L'ACIDE CARBOXYLIQUE POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：CELGENE CORP

  公开号：WO2022140555A1

  公开（公告）日：2022-06-30

  Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.

  本文提供了用于调节S1P5的化合物及其组合物。在某些实施例中，这些化合物和组合物被用于治疗神经系统疾病。